Phaseline

Companies › Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair: clinical trials, targets and expected readouts

3 active drug programs in 20 registered trials: 16 Phase 2, 3 Phase 3, 1 Phase 1; Oncology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Abiraterone
Cytochrome P450 17A1 inhibitor; Androgen Receptor antagonist; Steroid 5-alpha-reductase inhibitor
CYP17A1, AR, SRD5A1, SRD5A2, SRD5A3Phase 2Prostate Cancer; Metastatic Castration-resistant Prostate Cancer (mCRPC); Castration Levels of Testosterone; Advanced Prostate Adenocarcinoma …Nov 2026
Raloxifene
Estrogen receptor beta modulator; Estrogen receptor modulator
ESR2, ESR1Phase 2Breast Cancer; BPH (Benign Prostatic Hyperplasia); Brain TumorDec 2026
CEA protein antigen plus BCG Vaccine Mix
CEA antigen with trained immunity via BCG; APCs process CEA antigen into peptide fragments
CEAPhase 1Rectal CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06173362AbirateronePhase 2Advanced Prostate AdenocarcinomaOncologyNov 2026
NCT03348670AbirateronePhase 2Prostate CancerOncologyNov 2026
NCT02403505CEA protein antigen plus BCG Vaccine MixPhase 1Rectal CancerOncologyNov 2026
NCT03903835AbirateronePhase 3Metastatic Castration-resistant Prostate Cancer (mCRPC)OncologyDec 2026
NCT06655259AbirateronePhase 2Metastatic Prostate CancerOncologyDec 2026
NCT06062810RaloxifenePhase 2Breast CancerOncologyDec 2026
NCT07299292AbirateronePhase 2Prostate Cancer (Diagnosis)OncologyDec 2026
NCT04748042AbirateronePhase 2Prostate CancerOncologyMay 2027
NCT05189457AbirateronePhase 2Prostate CancerOncologyJul 2027
NCT06971211AbirateronePhase 2Metastatic Castration-resistant Prostate CancerOncologyOct 2027
NCT06832774AbirateronePhase 2Prostate Cancer Metastatic DiseaseOncologyDec 2027
NCT07815522AbirateronePhase 2Salivary Gland CarcinomaOncologyOct 2028
NCT06944145RaloxifenePhase 2BPH (Benign Prostatic Hyperplasia)GenitourinaryJun 2029
NCT07751133AbirateronePhase 3Prostate CancerOncologyAug 2029
NCT07470606RaloxifenePhase 2Brain TumorOncologyJul 2030
NCT00268476AbirateronePhase 2Prostate CancerOncologyDec 2030
NCT05404139AbirateronePhase 2Metastatic Prostate CancerOncologyFeb 2031
NCT03678025AbirateronePhase 3Castration Levels of TestosteroneOncologyApr 2033
NCT07237269AbirateronePhase 2Prostate CancerOncologyApr 2033
NCT06818682AbirateronePhase 2Prostate CarcinomaOncologyJan 2035

Targets

ESR2 (1) ESR1 (1) CEA (1) CYP17A1 (1) AR (1) SRD5A1 (1) SRD5A2 (1) SRD5A3 (1)

Companies with the same targets

AstraZeneca Pfizer Astellas Roche Novartis Johnson & Johnson (Janssen) Sun Pharmaceutical Industries Azure Biotech LeonaBio Alessa Therapeutics

Companies built like this

Alpheus Medical Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Neuboron Bio-SciTech Hrain Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.